In the past decade, treatment of staphylococcal infections has become more challenging due to the emergence of multidrug resistant/meticillin-resistant Staphylococcus aureus (MRSA) strains, community-associated (CA)-MRSA strains such as USA300 evolving resistance to non-b-lactams, reduced clinical response to vancomycin, and spread of resistance to alternative compounds, such as linezolid, daptomycin and mupirocin (Hill et al.